DALDA (BCH-150) manufacturers
- DALDA
-
- $1820.00 / 25mg
-
2025-10-27
- CAS:118476-85-0
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | DALDA (BCH-150) Basic information |
| Product Name: | DALDA (BCH-150) | | Synonyms: | tyrosyl-arginyl-phenylalanyl-lysinamide;(D-arg2,lys4) dermorphin fragment*1-4 amide;DALDA (BCH-150) >96% (D-ARG2,LYS4)DERMOR PH;DALDA (BCH-150);(D-Arg2,Lys4)-Dermorphin (1-4) amide H-Tyr-D-Arg-Phe-Lys-NH2;L-Lysinamide, L-tyrosyl-D-arginyl-L-phenylalanyl-;(D-Arg?,Lys?)-Dermorphin (1-4) amide | | CAS: | 118476-85-0 | | MF: | C30H45N9O5 | | MW: | 611.74 | | EINECS: | | | Product Categories: | | | Mol File: | 118476-85-0.mol |  |
| | DALDA (BCH-150) Chemical Properties |
| density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | Methanol (Sligthly), Water (Slightly) | | pka | 9.96±0.15(Predicted) | | form | solid | | color | white | | Stability: | Hygroscopic |
| | DALDA (BCH-150) Usage And Synthesis |
| Uses | (D-Arg2,Lys4)-Dermorphin (1-4) Amide H-Tyr-D-Arg-Phe-Lys-NH2 uses of collagen binding domains to deliver products to skin. | | in vivo | DALDA (0-7 nmol/rat; i.t.; once) shows antinociceptive and respiratory effects in rats[1].
DALDA (0.1 and 1.0 μg/side; ICV; once) results in biphasic effects, with an initial suppression, an intermediate marked inhibition, followed by activation for horizontal movement, rearing and stereotypy times in rats[2]. | Animal Model: | Male Sprague-Dawley rats (300–350 g)[1] | | Dosage: | 0.24, 0.7 and 7 nmol/rat | | Administration: | Intrathecal injection, once | | Result: | Showed antinociceptive effects with an ED50 of 237 pmol/rat in the rat tail-flick test. Inhibited the uptake of NE in spinal cord synaptosomes in a dose-dependent manner. Had no effect on 5-HT uptake. Produced depression in minute ventilation. |
| Animal Model: | Male Long-Evans rats, weighing 200-225 g[2] | | Dosage: | 0, 0.1 and 1.0 μg/side, 0.5 μL | | Administration: | Lateral cerebral ventricle injection, once | | Result: | Elicited a significant biphasic effect with an initial suppression, an intermediate marked inhibition, followed by significant activation for horizontal movement time, rearing time, and stereotypy time. |
| | IC 50 | μ Opioid Receptor/MOR: 1.69 nM (Ki); κ Opioid Receptor/KOR: 4230 nM (Ki); δ Opioid Receptor/DOR: 19200 nM (Ki) |
| | DALDA (BCH-150) Preparation Products And Raw materials |
|